The project will study myelin/ oligodendrocyte glycoprotein (MOG) which has been localized on the outermost wrap of the myelin sheath and identified as a major target involved in immune-mediated demyelination. The proposal has three Specific Aims that are overall designed 1) to advance the understanding of MOG and the role it plays in myelination and 2) to begin a molecular analysis of MOG's interactions with the oligodendroglial cytoskeleton. Since preliminary data indicate that MOG interacts with the cytoskeleton, the project will focus on MOG's putative cytoplasmic domains that are most likely to associate with the cytoskeleton.
In Aim 1, MOG's cytoplasmic domains will be mutagenized to generate constructs which in turn will be used to generate multiple stable transfectants of an immortalized oligodendrocyte cell line N20.1.
In Aim 2, MOG/cytoskeleton interactions will be analyzed in wildtype and variant MOG stably expressing N20.1 lines.
In Aim 3, the proposal will focus on characterizing molecules that associate with MOG's intracellular domains, utilizing co-immuno-precipitation and cross-linking experiments.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS035319-05
Application #
6151579
Study Section
Special Emphasis Panel (ZRG1-NLS-3 (01))
Program Officer
Behar, Toby
Project Start
1997-02-01
Project End
2001-09-29
Budget Start
2000-02-01
Budget End
2001-09-29
Support Year
5
Fiscal Year
2000
Total Cost
$154,722
Indirect Cost
Name
University of Iowa
Department
Pharmacology
Type
Schools of Medicine
DUNS #
041294109
City
Iowa City
State
IA
Country
United States
Zip Code
52242